Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

The global protein expression market is expected to reach USD 4.82 billion in 2029 from USD 3.41 billion in 2024 at a CAGR of ...

Agilent Technologies Inc. announces the new Mito-rOCR Assay Kit. This easy and streamlined end-to-end solution makes sophisticated analysis of mitochondrial function available to researchers of all ...

Shares of Agilent Technologies Inc. A inched 0.46% higher to $134.28 Wednesday, on what proved to be an all-around great ...

To make the analysis of genetics easier, the company's product line includes consumables, integrated systems, and analytical instrumentation. Genomics products are offered through the equipment and ...

CWA Asset Management Group LLC purchased a new position in Agilent Technologies, Inc. (NYSE:A – Free Report) in the 3rd ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

On Monday, Agilent Technologies Inc (A) stock saw a decline, ending the day at $133.86 which represents a decrease of $-2.82 or -2.06% from the prior close of $136.68. The stock opened at $137.2 and ...

Mettler-Toledo’s 2025 sales growth projection is 3%. Find out why MTD stock offers value despite global sales challenges, ...

Barclays analyst Luke Sergott maintained a Hold rating on Fortrea Holdings Inc. (FTRE – Research Report) on November 8 and set a price ...

Principal Financial Group Inc. trimmed its holdings in shares of Agilent Technologies, Inc. (NYSE:A – Free Report) by 83.0% ...